We subsequently sought to identify the most promising synthetic viability candidates by integrating cancer genomic and transcriptomic analyses with results from recent genome-wide CRISPR knockout screens in BRCA1 and BRCA2 knockout isogenic cell lines [42]. The gene discussed is BRCA2; the disease is cancer.